skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Indications of Carbon Ion Therapy at CNAO

Journal Article · · AIP Conference Proceedings
DOI:https://doi.org/10.1063/1.3120060· OSTI ID:21289559
 [1];  [2];  [1]
  1. Institute of Radiological Sciences, University of Milano, Via A. di Rudini 8, Milano 20142 (Italy)
  2. CNAO National Centre for Oncological Hadrontherapy, Via Caminadella 16, Milano 20123 (Italy)

CNAO will be a dual center capable of providing therapeutic beams of protons and carbon ions with maximum energy of 400 MeV/u. At the beginning, it will be equipped with three treatment rooms with fixed horizontal and vertical beam lines. In a subsequent phase, two more rooms with a rotating gantry are foreseen. An active spot scanning dose delivery system will be employed. Initially, 80% of the treatments will be carried out with carbon ions. All patients will be treated within clinical trials to assess carbon ion indications with an evidence-based methodology. Seven disease-specific working groups have been developed: lung tumors, liver tumors, sarcomas, head and neck tumors, central nervous system lesions, eye tumors and pediatric tumors. The last two groups will be treated mainly with protons. In the first phase, CNAO will focus on head and neck cancers, treating inoperable, residual or recurrent malignant salivary gland tumors, mucosal melanoma, adenocarcinoma and unfavorably located SCC (nasal and paranasal sinuses). Carbon ions will be employed as a boost in the treatment of locally advanced, poor prognosis, SCC of the hypopharynx and tongue base. Bone and soft tissue sarcomas of the extremity will be treated with a limb-sparing approach, and trunk sarcomas will be treated with exclusive or post-operative irradiation. Skull base tumors (chordoma and chondrosarcoma), recurrent or malignant meningioma and glial tumors will be treated with carbon ions. After sufficient expertise has been gained in coping with organ motion, CNAO will start treating thoracic and abdominal targets. HCC will be treated in inoperable patients with one or more lesions that can be included in a single CTV. Early stage NSCLC will be treated. In the second phase, two more groups on gynecological malignancies and digestive tumors (esophageal cancer, rectal cancer, pancreatic cancer) will be created.

OSTI ID:
21289559
Journal Information:
AIP Conference Proceedings, Vol. 1099, Issue 1; Conference: CAARI 2008: 12. international conference on application of accelerators in research and industry, Fort Worth, TX (United States), 10-15 Aug 2008; Other Information: DOI: 10.1063/1.3120060; (c) 2009 American Institute of Physics; Country of input: International Atomic Energy Agency (IAEA); ISSN 0094-243X
Country of Publication:
United States
Language:
English

Similar Records

Experience in charged particle irradiation of tumors of the skull base
Journal Article · Fri Jul 01 00:00:00 EDT 1994 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21289559

Comparison of clinical and laboratory data on neutron therapy for locally advanced tumors
Journal Article · Tue Dec 01 00:00:00 EST 1987 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:21289559

Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head-and-Neck Cancer: Final Analysis of a Phase I/II Trial
Journal Article · Sun Jan 01 00:00:00 EST 2012 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21289559